Balance Sheet
AssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Common Equity (2019 - 2025)

Benitec Biopharma's Common Equity history spans 7 years, with the latest figure at $97.6 million for Q1 2025.

  • For Q1 2025, Common Equity rose 748.43% year-over-year to $97.6 million; the TTM value through Mar 2025 reached $97.6 million, up 748.43%, while the annual FY2024 figure was $47.2 million, 23290.1% up from the prior year.
  • Common Equity for Q1 2025 was $97.6 million at Benitec Biopharma, up from $75.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $97.6 million in Q1 2025 and bottomed at $202000.0 in Q2 2023.
  • The 5-year median for Common Equity is $14.6 million (2022), against an average of $25.3 million.
  • The largest annual shift saw Common Equity crashed 92.99% in 2023 before it soared 23290.1% in 2024.
  • A 5-year view of Common Equity shows it stood at $10.8 million in 2021, then decreased by 17.0% to $9.0 million in 2022, then soared by 72.0% to $15.5 million in 2023, then skyrocketed by 390.89% to $75.9 million in 2024, then rose by 28.48% to $97.6 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Common Equity are $97.6 million (Q1 2025), $75.9 million (Q4 2024), and $64.2 million (Q3 2024).